Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) price on Thursday, December 26, rose 3.56% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.78.
A look at the stock’s price movement, the close in the last trading session was $0.76, moving within a range at $0.7 and $0.7954. The beta value (5-Year monthly) was 1.244. Turning to its 52-week performance, $3.73 and $0.62 were the 52-week high and 52-week low respectively. Overall, LXRX moved -3.49% over the past month.
Lexicon Pharmaceuticals Inc’s market cap currently stands at around $283.70 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 6.48M for the company’s revenue for the quarter, with a low and high estimate of 2M and 26.7M respectively. The average forecast suggests up to a 822.99% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 11.13M, representing a 824.52% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LXRX is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend LXRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
LXRX’s current price about 3.66% and -31.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 44.53, while 7-day volatility ratio is 15.10% and 13.34% in the 30-day chart. Further, Lexicon Pharmaceuticals Inc (LXRX) has a beta value of 1.06, and an average true range (ATR) of 0.11. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -669.23% off current price level while to achieve the yearly target high, price needs to move -669.23%. Nonetheless, investors will most likely welcome a -669.23% jump to $6 which is the analysts’ median price.
If we refocus on Lexicon Pharmaceuticals Inc (NASDAQ:LXRX), historical trading data shows that trading volumes averaged 7.63 over the past 10 days and 4.23 million over the past 3 months. The company’s latest data on shares outstanding shows there are 361.49 million shares.
The 53.33% of Lexicon Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 29.64% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 31.53 million on 2024-11-29, giving us a short ratio of 7.06. The data shows that as of 2024-11-29 short interest in Lexicon Pharmaceuticals Inc (LXRX) stood at 1935.0000000000002 of shares outstanding, with shares short rising to 28.65 million registered in 2024-10-31. Current price change has pushed the stock -48.71% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LXRX stock continues to rise going into the next quarter.